These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Pathogenesis of proliferative vitreoretinopathy. Modulation of retinal pigment epithelial cell functions by vitreous and macrophages. Kirchhof B; Sorgente N Dev Ophthalmol; 1989; 16():1-53. PubMed ID: 2676632 [TBL] [Abstract][Full Text] [Related]
3. [Evaluation of experimental proliferative vitreoretinopathy in rabbits]. Kuriyama S; Ohuchi T; Okada M; Yamakawa R; Yoshimura N; Honda Y Nippon Ganka Gakkai Zasshi; 1990 Sep; 94(9):792-8. PubMed ID: 2248164 [TBL] [Abstract][Full Text] [Related]
4. EIU in the rat promotes the potential of syngeneic retinal cells injected into the vitreous cavity to induce PVR. Behar-Cohen FF; Thillaye-Goldenberg B; de Bizemont T; Savoldelli M; Chauvaud D; de Kozak Y Invest Ophthalmol Vis Sci; 2000 Nov; 41(12):3915-24. PubMed ID: 11053294 [TBL] [Abstract][Full Text] [Related]
5. Fluorouracil therapy for proliferative vitreoretinopathy after vitrectomy. Stern WH; Lewis GP; Erickson PA; Guerin CJ; Anderson DH; Fisher SK; O'Donnell JJ Am J Ophthalmol; 1983 Jul; 96(1):33-42. PubMed ID: 6869478 [TBL] [Abstract][Full Text] [Related]
6. Quantitative assessment of growth stimulating activity of the vitreous during PVR. Yang CM; Cousins SW Invest Ophthalmol Vis Sci; 1992 Jul; 33(8):2436-42. PubMed ID: 1634341 [TBL] [Abstract][Full Text] [Related]
8. Evaluation of drug treatments for proliferative vitreoretinopathy using vitreous microtensiometry. Moorhead LC; Sepahban S; Armeniades CD Ann Ophthalmol; 1991 Sep; 23(9):349-55. PubMed ID: 1741609 [TBL] [Abstract][Full Text] [Related]
9. The role of breakdown of the blood-retinal barrier in cell-injection models of proliferative vitreoretinopathy. Sen HA; Robertson TJ; Conway BP; Campochiaro PA Arch Ophthalmol; 1988 Sep; 106(9):1291-4. PubMed ID: 3415556 [TBL] [Abstract][Full Text] [Related]
10. Proliferative vitreoretinopathy in the Swine-a new model. Umazume K; Barak Y; McDonald K; Liu L; Kaplan HJ; Tamiya S Invest Ophthalmol Vis Sci; 2012 Jul; 53(8):4910-6. PubMed ID: 22729438 [TBL] [Abstract][Full Text] [Related]
12. Proliferative vitreo-retinal disorders: experimental models in vivo and in vitro. Martini B Acta Ophthalmol Suppl (1985); 1992; (201):1-63. PubMed ID: 1322004 [TBL] [Abstract][Full Text] [Related]
14. Proliferative vitreoretinopathy (PVR): a personal account of its pathogenesis and treatment. Proctor lecture. Machemer R Invest Ophthalmol Vis Sci; 1988 Dec; 29(12):1771-83. PubMed ID: 3056866 [No Abstract] [Full Text] [Related]
15. [Autotransplantation of the retinal pigment epithelium (RPE). A contribution on the MVR problem]. Mueller-Jensen K; Machemer R Ber Zusammenkunft Dtsch Ophthalmol Ges; 1975; (73):422-6. PubMed ID: 1242956 [No Abstract] [Full Text] [Related]
16. Antiproliferative effect of mitomycin C on experimental proliferative vitreoretinopathy in rabbits. Yu HG; Chung H Korean J Ophthalmol; 1997 Dec; 11(2):98-105. PubMed ID: 9510652 [TBL] [Abstract][Full Text] [Related]
17. Biodegradable microspheres containing adriamycin in the treatment of proliferative vitreoretinopathy. Moritera T; Ogura Y; Yoshimura N; Honda Y; Wada R; Hyon SH; Ikada Y Invest Ophthalmol Vis Sci; 1992 Oct; 33(11):3125-30. PubMed ID: 1399416 [TBL] [Abstract][Full Text] [Related]